-
FDA Grants Priority Review to Pfizer and Astellas’ Xtandi for High-Risk Prostate Cancer
•
The US Food and Drug Administration (FDA) has granted priority review status to the submission by pharmaceutical partners Pfizer (NYSE: PFE) and Astellas (TYO: 4503) for their drug combination of Xtandi (enzalutamide) and leuprolide. This treatment is intended for patients with non-metastatic castration-sensitive prostate cancer (nmCSPC) who are at high…
-
Scott-Moncrieff & Associates Preparing 50 Cases Against AstraZeneca Over Vaccine Concerns
•
Scott-Moncrieff & Associates, a UK-based law firm, has disclosed that it is preparing nearly 50 cases against pharmaceutical giant AstraZeneca (AZ, NASDAQ: AZN) in relation to its SARS-CoV-2 vaccine. The move follows the filing of a product liability claim by a plaintiff earlier this month, who alleged that his wife’s…
-
Nanjing F&S Pharmatech Secures First Generic Approval for Novartis’s Entresto in China
•
Nanjing F&S Pharmatech Co., Ltd, a China-based pharmaceutical company, has announced that it has received market approval from the National Medical Products Administration (NMPA) for its generic version of Novartis’s (NYSE: NVS) heart failure therapy, Entresto (sacubitril, valsartan). This marks a significant milestone as Nanjing F&S’s version, an in-house developed…
-
WuXi Biologics Reports 17.8% Revenue Growth and Expands Service Scope in H1 2023
•
China-based Contract Research, Development, and Manufacturing Organization (CRDMO) WuXi Biologics (HKG: 2269) has released its unaudited interim financial report for the period ended June 30, 2023. The report indicates a 17.8% year-on-year (YOY) increase in revenues, reaching RMB 8.49 billion (USD 1.17 billion). This growth is attributed to the successful…
-
Johnson & Johnson Completes Spinoff of Kenvue as Independent Company
•
Global healthcare giant Johnson & Johnson (J&J, NYSE: JNJ) has completed the separation of its consumer healthcare business, Kenvue (NYSE: KVUE), as an independent entity. The transaction involved the exchange of 191 million J&J shares for 1.5 billion shares of Kenvue, with J&J retaining a 9.5% stake in the newly…
-
Everest Medicines Reports Q1 2023 Revenue Growth and Pipeline Progress
•
China-based Everest Medicines (HKG: 1952) has announced its financial and corporate update for the first half of 2023. The company reported a revenue increase of RMB 7.9 million, reaching RMB 8.9 million (USD 1.23 million) for the six-month period. This growth was primarily attributed to the sales of Xerava and…
-
Lynk Pharmaceuticals’ LNK01001 Shows Positive Results in Ankylosing Spondylitis Phase II Study
•
China-based Lynk Pharmaceuticals Co., Ltd has announced positive topline results from the Phase II clinical study of its pipeline candidate, LNK01001, in the treatment of ankylosing spondylitis (AS). The randomized, double-blind, placebo-controlled, multi-center study involved 177 AS patients who had previously experienced insufficient efficacy or intolerance to non-steroidal anti-inflammatory drugs…
-
Allist Pharmaceuticals’ Furmonertinib Wins NMPA Nod for EGFR-Mutated NSCLC Treatment
•
Shanghai-based Allist Pharmaceuticals Inc. (SHA: 688578) has announced that it has received clinical approval from the National Medical Products Administration (NMPA) for its drug furmonertinib. The drug is indicated for the first-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR PACC mutation or EGFR L861Q…
